Advertisement
KMDA vs PRFX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Buy and PRFX is a Hold.
KMDA's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for KMDA moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 17 similar instances when the indicator left oversold territory. In 12 of the 17 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 66 cases where KMDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on KMDA as a result. In 61 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for KMDA just turned positive on November 10, 2026. Looking at past instances where KMDA's MACD turned positive, the stock continued to rise in 36 of 52 cases over the following month. The odds of a continued upward trend are 69%.
KMDA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where KMDA advanced for three days, in 172 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
KMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for KMDA crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KMDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
The Aroon Indicator for KMDA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.548) is normal, around the industry mean (6.379). P/E Ratio (19.026) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.644) is also within normal values, averaging (2.202). Dividend Yield (0.094) settles around the average of (0.062) among similar stocks. P/S Ratio (2.487) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. KMDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PRFX in -8.51% downward trend, sliding for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PRFX declined for three days, in 358 of 379 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
PRFX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRFX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRFX's RSI Indicator exited the oversold zone, 44 of 52 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PRFX as a result. In 84 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for PRFX just turned positive on October 28, 2026. Looking at past instances where PRFX's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRFX advanced for three days, in 154 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.192) is normal, around the industry mean (6.379). P/E Ratio (-0.213) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (34.722) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PRFX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
KMDA | PRFX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 35 Fair valued | |
PROFIT vs RISK RATING 1..100 | 39 | 100 | |
SMR RATING 1..100 | 76 | 98 | |
PRICE GROWTH RATING 1..100 | 49 | 82 | |
P/E GROWTH RATING 1..100 | 62 | 100 | |
SEASONALITY SCORE 1..100 | 32 | 6 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KMDA's Valuation (11) in the Biotechnology industry is in the same range as PRFX (35) in the null industry. This means that KMDA’s stock grew similarly to PRFX’s over the last 12 months.
KMDA's Profit vs Risk Rating (39) in the Biotechnology industry is somewhat better than the same rating for PRFX (100) in the null industry. This means that KMDA’s stock grew somewhat faster than PRFX’s over the last 12 months.
KMDA's SMR Rating (76) in the Biotechnology industry is in the same range as PRFX (98) in the null industry. This means that KMDA’s stock grew similarly to PRFX’s over the last 12 months.
KMDA's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for PRFX (82) in the null industry. This means that KMDA’s stock grew somewhat faster than PRFX’s over the last 12 months.
KMDA's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for PRFX (100) in the null industry. This means that KMDA’s stock grew somewhat faster than PRFX’s over the last 12 months.
| KMDA | PRFX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 68% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 68% | 15 days ago 83% |
| Declines ODDS (%) | 9 days ago 62% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KMDA’s FA Score shows that 1 FA rating(s) are green while PRFX’s FA Score has 0 green FA rating(s).
- KMDA’s FA Score: 1 green, 4 red.
- PRFX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KMDA’s TA Score shows that 7 TA indicator(s) are bullish while PRFX’s TA Score has 4 bullish TA indicator(s).
- KMDA’s TA Score: 7 bullish, 3 bearish.
- PRFX’s TA Score: 4 bullish, 4 bearish.
Price Growth
KMDA (@Pharmaceuticals: Generic) experienced а +11.72% price change this week, while PRFX (@Pharmaceuticals: Generic) price change was +12.07% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
KMDA is expected to report earnings on Mar 17, 2027.
PRFX is expected to report earnings on Nov 19, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
PRFX and
Correlation & Price change
A.I.dvisor tells us that PRFX and AMRX have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRFX and AMRX's prices will move in lockstep.
| Ticker / NAME | Correlation To PRFX | 1D Price Change % | ||
|---|---|---|---|---|
| PRFX | 100% | -1.79% | ||
| AMRX - PRFX | 24% Poorly correlated | +0.47% | ||
| INCR - PRFX | 22% Poorly correlated | +3.58% | ||
| LFCR - PRFX | 21% Poorly correlated | N/A | ||
| KMDA - PRFX | 21% Poorly correlated | +5.06% | ||
| SUPN - PRFX | 21% Poorly correlated | +4.09% | ||
More | ||||